Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis

Clinical Rheumatology

Volumn 34, Issue 6, 2015, Pages 1019-1023

  Raychaudhuri, Smriti K ^a,b   Saxena, Ankit ^c   Raychaudhuri, Siba P ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ankylosing spondylitis; IL 17; Psoriasis; Psoriatic arthritis; Th17

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 23;

ANKYLOSING SPONDYLITIS; ARTICLE; BONE EROSION; CLINICAL FEATURE; FIBROBLAST; HUMAN; HUMAN CELL; MEMORY T LYMPHOCYTE; NONHUMAN; OSSIFICATION; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SYNOVIAL FLUID; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; ANIMAL; IMMUNOLOGY; SPONDYLOARTHROPATHY;

ANIMALS; ARTHRITIS, PSORIATIC; HUMANS; INTERLEUKIN-17; INTERLEUKIN-23; SPONDYLARTHROPATHIES; TH17 CELLS;

EID: 84929946870     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-015-2961-7     Document Type: Article

References (61)

1. Appel H, Kuhne M, Spiekermann S, Ebhardt H, Grozdanovic Z, Köhler D, Dreimann M, Hempfing A, Rudwaleit M, Stein H, Metz-Stavenhagen P, Sieper J, Loddenkemper C (2006) Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum 54(9):2845–51
2. Lowes MA, Bowcock AM, Krueger JG (2007) Pathogenesis and therapy of psoriasis. Nature 445(7130):866–73
3. Raychaudhuri SP (2013) A cutting edge overview: psoriatic disease. Clin Rev Allergy Immunol 44(2):109–13
4. Griffiths CE, Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370(9583):263–71
5. Liu Y, Krueger JG, Bowcock AM (2007) Psoriasis: genetic associations and immune system changes. Genes Immun 8(1):1–12
6. Gladman DD, Farwell VT, Pellett F, Schentag C, Raham P (2003) HLA is a candidate region for psoriatic arthritis. evidence for excessive HLA sharing in sibling pairs. Hum Immunol 64(9):887–9
7. Amherd-Hoekstra A, Naher H, Lorenz HM, Enk AH (2010) Psoriatic arthritis: a review. J Dtsch Dermatol Ges 8(5):332–9
8. Raychaudhuri SP (2013) Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 44:183–93
9. Raychaudhuri SP, Jiang WY, Raychaudhuri SK (2008) Revisiting the Koebner phenomenon: role of NGF and its receptor system in the pathogenesis of psoriasis. Am J Pathol 172(4):961–71
10. Raychaudhuri SP, Kundu-Raychaudhuri S, Tamura K, Masunaga T, Kubo K, Hanaoka K et al (2008) FR255734, a humanized, Fc-Silent, anti-CD28 antibody, improves psoriasis in the SCID mouse-psoriasis xenograft model. J Invest Dermatol 128(8):1969–76. doi:10.1038/jid.2008.38
11. Raychaudhuri SP, Mitra A, Datta Mitra A, Abria C, Raychaudhuri SK (2014) Th9 cells in inflammatory cascades of autoimmune arthritis. Arthritis Rheum 66(11):S708, Abstract 1602
12. Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG (2013) The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 34(4):174–81
13. Kruithof E, Baeten D, Van den Bosch F, Mielants H, Veys EM, De Keyser F (2005) Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis 64:529–36
14. Raychaudhuri SP, Raychaudhuri SK (2004) Role of NGF and neurogenic inflammation in the pathogenesis of psoriasis. Prog Brain Res 146:433–7
15. Elder JT, Bruce AT, Gudjonsson JE, Johnston A, Stuart PE, Tejasvi T et al (2010) Molecular dissection of psoriasis: integrating genetics and biology. J Invest Dermatol 130(5):1213–26
16. Chandran V, Raychaudhuri SP (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34(3):J314–21
17. Bowes J, Orozco G, Flynn E, Ho P, Brier R, Marzo-Ortega H et al (2011) Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Ann Rheum Dis 70:1641–4
18. Filer C, Ho P, Smith RL, Griffiths C, Young HS, Worthington J et al (2012) Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum 64(4):1302
19. Huffmeier U, Uebe S, Ekici AB, Bowes J, Giardina E, Korendowych E et al (2010) Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 42:996–9
20. WTCCC & TASC (2007) Association scan of 14,500 nonsynonymous SNPs in four diseases identifiesautoimmunity variants. Nat Genet 39:1329–1337
21. Mitra A, Raychaudhuri SK, Raychaudhuri SP (2012) Functional role of IL-22 in psoriatic arthritis. Arthritis Res Ther 14(2):R65
22. Lories RJ, McInnes IB (2012) Primed for inflammation: enthesis-resident T cells. Nat Med 18(7):1018–9
23. Baeten D, Braun J, Baraliakos X et al (2014) Secukinumab, a monoclonal antibody to interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a 52-week phase 3 randomized placebo-controlled trial with intravenous loading and subcutaneous maintenance dosing. Arthritis Rheum 66:S360, Abstract 819
24. Sieper J, Braun J, Baraliakos X et al (2014) Secukinumab, a monoclonal antibody to interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a phase 3, randomized, placebo-controlled trial with subcutaneous loading and maintenance dosing. Arthritis Rheum 66:S232, Abstract 536
25. Mease PJ, Genovese MC, Greenwalk MW, Ritchlin CT, Beaulier AD, Deodhar A et al (2014) Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 370(24):2295–306
26. Papp KA, Leonardi C, Menter A, Ortonne JP, Kreuger JG, Kricorian G et al (2012) Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 366(13):1181–9
27. Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK et al (1995) Human IL-17: a novel cytokine derived from T cells. J Immunol 155(12):5483–6
28. Tesmer LA, Lundy SK, Sarkar S, Fox DA (2008) Th17 cells in human disease. Immunol Rev 223:87–113
29. Kuestner RE, Taft DW, Haran A, Brandt CS, Brender T, Lum K et al (2007) Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17 F. J Immunol 179(8):5462–73
30. Liang SC, Long AJ, Bennett F, Whitters MJ, Karim R, Collins M et al (2007) An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J Immunol 179(11):7791–9
31. Hymowitz SG, Filvaroff EH, Jp Y, Lee J, Cai L, Risser P et al (2001) IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J 20(19):5332–41
32. Yao Z, Spriggs MK, Derry JM, Strockbine L, Park LS, Vanden Bos T et al (1997) Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine 9(11):794–800
33. Ely LK, Fischer S, Garcia KC (2009) Structural basis of receptor sharing by interleukin 17 cytokines. Nat Immunol 10(12):1245–51
34. Toy D, Kugler D, Wolfson M, Vanden Bos T, Gurgel J, Derry J et al (2006) Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 177(1):36–9
35. Coimbra S, Figueriredo A, Castro E, Rocha-Pereira P, Santos-Silva A (2012) The roles of cells and cytokines in the pathogenesis of psoriasis. Int J Dermatol 51(4):389–95, quiz 395-8
36. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F et al (2004) Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199(1):125–30
37. Piskin G, Sylva-Steenland R, Bos JD, Teunissen MB (2006) In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 176(3):1908–15
38. Bovenschen HJ, van de Kerkhof PC, van Erp PE, Woestenenk R, Joosten I, Koenen HJ (2011) Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol 131(9):1853–60
39. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein W, Mattson JD et al (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8(9):950–7
40. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS et al (2008) Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 128(5):1207–11
41. Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K (2009) Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol 160(2):319–24
42. van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD et al (2009) Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 182(9):5836–45
43. Homey B, Dieu-Nosjean MC, Wiesenborn A, Massacrier C, Pin JJ, Oldham E et al (2000) Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 164(12):6621–32
44. Girolomoni G, Mrowietz U, Paul C (2012) Psoriasis: rationale for targeting interleukin-17. Br J Dermatol 167(4):717–24
45. Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan K, Suarex-Farinas M, Cardinale I et al (2008) Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 159(5):1092–102
46. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M et al (2006) Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203(10):2271–9
47. Gutowska-Owsiak D, Schaupp AL, Salimi M, Selvakumar TA, McPherson T, Taylor S et al (2012) IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol 21(2):104–10
48. Raychaudhuri SP, Raychaudhuri SK, Genovese MC (2012) IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 359(1-2):419–29
49. Chabaud M, Lubberts E, Joosten L, van den Berg W, Miossec P (2001) IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 3:168–177
50. Koshy PJ, Henderson N, Logan C, Life PF, Cawston TE, Rowan AD (2002) IL-17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis 61(8):704–713
51. Nakae S, Nambu A, Sudo K, Iwakura Y (2003) Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171(11):6173–6177
52. Koenders MI, Kolls JK, Oppers-Walgreen B, van den Bersselaar L, Joosten LA, Schurr JR et al (2005) Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated Streptococcal cell wall induced arthritis. Arthritis Rheum 52(10):3239–3247
53. Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Di Padova FE et al (2005) Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 167(1):141–149
54. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S et al (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103(9):1345–1352
55. Australo-Anglo-American Spondyloarthritis Consortium (TASC), Reveille JD, Sims AM, Danoy P, Evans DM, Leo P, Pointon JJ et al (2010) Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet 42(2):123–127
56. Mei Y, Pan F, Gao J, Ge R, Duan Z, Zeng Z, Liao F, Xia G, Wang S, Xu S, Xu J, Zhang L, Ye D (2011) Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol 30:269–273
57. Zeng L, Lindstrom MJ, Smith JA (2011) Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide. Arthritis Rheum 63(12):3807–17
58. Appel H, Maier R, Wu P, Scheer R, Hempfing A, Kayser R, Thiel A, Radbruch A, Loddenkemper C, Sieper J (2011) Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 13:R95
59. Singh AK, Misra R, Aggarwal A (2011) Th17 associated cytokines in patients with reactive arthritis/undifferentiated spondylarthropathy. Clin Rheumatol 30:771–776
60. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM (2003) Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111(6):821–31
61. Sherlock JP, Joyce-Shaikh B, Turner SP et al (2012) IL-23 induces spondyloarthropathy by acting on ROR-gammatþ CD3þCD4-CD8- entheseal resident T cells. Nat Med 18:1069–1076